Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Najla Al Ali

Showing results (11-20 of 81) with videos related to

Pageof 9
Sort By:
Hematology (Amsterdam, Netherlands)|May 24, 2021
Impact of obesity on survival of patients with myelodysplastic syndromesZaker Schwabkey, Najla Al Ali, David Sallman, et al.
Leukemia|June 23, 2020
Characterization of myelodysplastic syndromes (MDS) with T-cell large granular lymphocyte proliferations (LGL)Rami S Komrokji, Najla Al Ali, David Sallman, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary TaleHanadi Ramadan, Vu H Duong, Najla Al Ali, et al.
Leukemia & Lymphoma|April 21, 2020
A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failureVu H Duong, Najla Al Ali, Ling Zhang, et al.
Cancer|September 30, 2011
Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndromeRami S Komrokji, Maria Corrales-Yepez, Najla Al Ali, et al.
Blood Cancer Journal|November 4, 2022
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndromeRami S Komrokji, Avani M Singh, Najla Al Ali, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 4, 2022
Comparison of Different Treatment Strategies for Blast-Phase Myeloproliferative NeoplasmsFranco Castillo Tokumori, Najla Al Ali, Onyee Chan, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 12, 2020
Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in MyelofibrosisFranco Castillo-Tokumori, Chetasi Talati, Najla Al Ali, et al.
British Journal of Haematology|June 24, 2022
Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromesVirginia O Volpe, Najla Al Ali, Onyee Chan, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 26, 2018
Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium AnalysisYazan Migdady, John Barnard, Najla Al Ali, et al.
Pageof 9

Showing results (11-20 of 81) with videos related to

Sort By:
Pageof 9
Hematology (Amsterdam, Netherlands)|May 24, 2021
Impact of obesity on survival of patients with myelodysplastic syndromesZaker Schwabkey, Najla Al Ali, David Sallman, et al.
Leukemia|June 23, 2020
Characterization of myelodysplastic syndromes (MDS) with T-cell large granular lymphocyte proliferations (LGL)Rami S Komrokji, Najla Al Ali, David Sallman, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 14, 2016
Eltrombopag Use in Patients With Chronic Myelomonocytic Leukemia (CMML): A Cautionary TaleHanadi Ramadan, Vu H Duong, Najla Al Ali, et al.
Leukemia & Lymphoma|April 21, 2020
A sequential two-stage dose escalation study of eltrombopag in patients with myelodysplastic syndrome and thrombocytopenia after hypomethylating agent failureVu H Duong, Najla Al Ali, Ling Zhang, et al.
Cancer|September 30, 2011
Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndromeRami S Komrokji, Maria Corrales-Yepez, Najla Al Ali, et al.
Blood Cancer Journal|November 4, 2022
Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndromeRami S Komrokji, Avani M Singh, Najla Al Ali, et al.
Clinical Lymphoma, Myeloma & Leukemia|March 4, 2022
Comparison of Different Treatment Strategies for Blast-Phase Myeloproliferative NeoplasmsFranco Castillo Tokumori, Najla Al Ali, Onyee Chan, et al.
Clinical Lymphoma, Myeloma & Leukemia|August 12, 2020
Retrospective Analysis of the Clinical Use and Benefit of Lenalidomide and Thalidomide in MyelofibrosisFranco Castillo-Tokumori, Chetasi Talati, Najla Al Ali, et al.
British Journal of Haematology|June 24, 2022
Splicing factor 3B subunit 1 (SF3B1) mutation in the context of therapy-related myelodysplastic syndromesVirginia O Volpe, Najla Al Ali, Onyee Chan, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 26, 2018
Clinical Outcomes With Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes: MDS Clinical Research Consortium AnalysisYazan Migdady, John Barnard, Najla Al Ali, et al.
Pageof 9